Eric Lloyd

1.6k total citations
22 papers, 975 citations indexed

About

Eric Lloyd is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. According to data from OpenAlex, Eric Lloyd has authored 22 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 9 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Nutrition and Dietetics. Recurrent topics in Eric Lloyd's work include Blood Pressure and Hypertension Studies (9 papers), Hormonal Regulation and Hypertension (8 papers) and Sodium Intake and Health (7 papers). Eric Lloyd is often cited by papers focused on Blood Pressure and Hypertension Studies (9 papers), Hormonal Regulation and Hypertension (8 papers) and Sodium Intake and Health (7 papers). Eric Lloyd collaborates with scholars based in United States, Switzerland and United Kingdom. Eric Lloyd's co-authors include H. Ralph Schumacher, Christopher Lademacher, Michael A. Becker, Patricia MacDonald, Alvin F. Wells, Luis R. Espinoza, D. Martin Watterson, Kathleen Somera-Molina, Mark S. Wainwright and Linda J. Van Eldik and has published in prestigious journals such as Hypertension, The Journal of Infectious Diseases and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Eric Lloyd

22 papers receiving 927 citations

Peers

Countries citing papers authored by Eric Lloyd

Since Specialization

Citations

This map shows the geographic impact of Eric Lloyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Lloyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Lloyd more than expected).

Fields of papers citing papers by Eric Lloyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Lloyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Lloyd. The network helps show where Eric Lloyd may publish in the future.

Co-authorship network of co-authors of Eric Lloyd

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Lloyd. A scholar is included among the top collaborators of Eric Lloyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Lloyd. Eric Lloyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial 2024 ·Vaccine ·(unknown), Shibadas Biswal, Eric Lloyd, Vianney Tricou, Nicolas Folschweiller	7
2	In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management 2023 ·Blood Cancer Journal ·Robert M. Rifkin, Saulius Girnius, Stephen J. Noga, Ruemu Birhiray, Suman Kambhampati, Sudhir Manda, Roger M. Lyons, Habte Yimer, (unknown), Eric Lloyd, (unknown), Joshua Richter	2
3	A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder 2022 ·Journal of Child and Adolescent Psychopharmacology ·Ann Childress, Eric Lloyd, Steve A. Johnson, Lhanoo Gunawardhana, Valerie Arnold	4
4	Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder 2022 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Ann Childress, Eric Lloyd, Leslie K. Jacobsen, Lhanoo Gunawardhana, Steve A. Johnson, Robert L. Findling	12
5	Cognitive Profiling and Personalized Therapy Recommendation for Dementia through a Language Aware Multi-Model Artificially Intelligent System 2022 ·(unknown), Jason Zhang, Eric Lloyd	1
6	Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults 2020 ·Vaccine ·James Sherwood, Paul M. Mendelman, Eric Lloyd, Mengya Liu, John W. Boslego, Astrid Borkowski, (unknown), Dennis J. Faix	55
7	Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination 2019 ·The Journal of Infectious Diseases ·Robert L. Atmar, Frank Baehner, Jakob P. Cramer, Eric Lloyd, James Sherwood, Astrid Borkowski, Paul M. Mendelman, (unknown), Mohamed Al‐Ibrahim, David L. Bernstein, Donald M. Brandon, Laurence Chu, Matthew Davis, (unknown), Sharon E. Frey, Jeffrey B. Rosen, John J. Treanor	22
8	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension 2018 ·The American Journal of Cardiology ·Keith C. Ferdinand, George L. Bakris, William C. Cushman, Michael A. Weber, Eric Lloyd, Jingtao Wu, William B. White	4
9	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension 2018 ·Journal of Hypertension ·William C. Cushman, George L. Bakris, William B. White, Michael A. Weber, Domenic Sica, Andrew W. Roberts, Eric Lloyd, Stuart Kupfer	6
10	Efficacy and safety of azilsartan medoxomil/chlortalidone fixed‐dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial 2018 ·Journal of Clinical Hypertension ·David Collier, Attila Juhász, Enrico Agabiti‐Rosei, Eric Lloyd, Michie Hisada, (unknown), Stuart Kupfer, Mark J. Caulfield	5
11	Long‐term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease 2018 ·Journal of Clinical Hypertension ·George L. Bakris, (unknown), Stuart Kupfer, Attila Juhász, Michie Hisada, Eric Lloyd, Suzanne Oparil	10
12	Comparison of long‐term safety of fixed‐dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide 2017 ·Journal of Clinical Hypertension ·Joel M. Neutel, William C. Cushman, Eric Lloyd, Bruce O. Barger, (unknown)	9
13	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes 2016 ·Journal of Hypertension ·William B. White, (unknown), Eric Lloyd, George L. Bakris, Stuart Kupfer	26
14	Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study 2016 ·Clinical and Experimental Hypertension ·(unknown), Eric Lloyd, Andrew W. Roberts, Bruce O. Barger	7
15	Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension 2012 ·Hypertension ·William C. Cushman, George L. Bakris, William B. White, Michael A. Weber, Domenic Sica, Andrew W. Roberts, Eric Lloyd, Stuart Kupfer	54
16	The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial 2010 ·Arthritis Research & Therapy ·Michael A. Becker, H. Ralph Schumacher, Luis R. Espinoza, Alvin F. Wells, Patricia MacDonald, Eric Lloyd, Christopher Lademacher	381
17	Tissue Doppler Measurements Correlate With Central Venous Pressure in Pediatric Patients After Cardiac Surgery 2010 ·ASAIO Journal ·(unknown), Andrew R. Yates, Lisa Nicholson, (unknown), Eric Lloyd, L. Clifford	6
18	Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout 2009 ·The Journal of Rheumatology ·Michael A. Becker, H. Ralph Schumacher, Patricia MacDonald, Eric Lloyd, Christopher Lademacher	200
19	Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury 2008 ·Journal of Neuroinflammation ·Eric Lloyd, Kathleen Somera-Molina, Linda J. Van Eldik, D. Martin Watterson, Mark S. Wainwright	149
20	Publication Rates of Scientific Presentations at the American Association of Hip and Knee Surgeons Annual Meetings from 1996 to 2001 2007 ·The Journal of Arthroplasty ·Eric Lloyd, Jeffrey L. Geller, Richard Iorio, Richard S. Yoon, Michael H. Huo, William Macaulay	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact